Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated February 5, 2026. The report discloses transactions in Novo Nordisk shares by board members, executives, and associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The transactions reported occurred on February 4, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of insider trading activity.
The filing details the following transaction metrics:
- Instrument: Novo Nordisk B Shares (DK0062498333).
- Transaction Types: Transfers of shares under the Long Term Incentive Programme (LTIP) and sales of shares to cover taxes on LTIP awards.
- Transaction Price: DKK 0.00 for transfers; DKK 304.72 for tax-cover sales.
- Transaction Venue: Outside a trading venue for transfers; Nasdaq Copenhagen for sales.
Material Changes
The filing does not provide comparative financial data or discuss material changes in the company's business operations versus prior periods. It solely reports specific share transactions executed on February 4, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The "About Novo Nordisk" section reiterates the company's purpose to defeat serious chronic diseases and notes it employs approximately 68,800 people in 80 countries.
Important Facts for Investors to Verify
- Insider Activity: Multiple executives, including CEO Maziar Mike Doustdar, CFO Karsten Munk Knudsen, and EVP David Moore, received share transfers under the LTIP and sold portions of these shares to cover tax liabilities.
- Transaction Volume: A total of 135,219 shares were transferred at no cost (DKK 0.00) to executives. Additionally, 10,490 shares were sold on the open market to cover taxes, generating approximately DKK 3,196,559.80 in proceeds.
- Market Price: The sales to cover taxes were executed at a price of DKK 304.72 per share on Nasdaq Copenhagen.
- Regulatory Compliance: All transactions were reported as initial notifications under market abuse regulations.